The small-molecule FDA-approved drugs for AML, beyond standard chemotherapy, include IDH inhibitors [41] (olutasidenib, ivosidenib, enasidenib), FLT3 inhibitors [40] (gilteritinib, midostaurin), BCL-2 inhibitor [42] (venetoclax), hypomethylating agents [39] (azacitidine, decitabine), and CPX-351 (liposomal cytarabine and daunorubicin) [43]. Here, IDH2 is linked to acute myeloid leukemia.